About this Research Topic
Given the success of the Multi-organ Linkage Pathophysiology and Therapy for NAFLD and NASH, we are pleased to announce the launch of Volume II.
MASLD and MASH refer to the hepatic phenotype of metabolic syndromes strongly associated with obesity, diabetes, and dyslipidemia. MASLD and MASH have complex pathogenesis modulated not only by the liver but also by muscle, adipose tissue, pancreas, gut microbiome, and immune and central nervous systems. This complex pathology, coupled with insulin resistance, lipid and bile acid changes, and congenital genetic predisposition, induces liver injury due to oxidative stress, endoplasmic reticulum stress, and autophagy dysfunction. Additionally, MASLD and MASH contribute to diseases such as cirrhosis, atherosclerosis, chronic kidney disease, lung disease, and cancer in various organs, leading to systemic multi-organ damage. Even though enthusiastic development of new drugs for MASLD and MASH has been underway, we are still lacking progress in generating therapeutic agents based on multiorgan-related pathomechanisms. In this special issue, we welcome clinical and basic studies on extrahepatic lesions, as well as new findings related to liver pathology in MASLD and MASH. Topic Editors welcome manuscripts that particularly focus on new therapies and new signaling pathways related to the multiorgan-linkage of MASLD and MASH.
MASLD and MASH refer to the hepatic phenotype of metabolic syndromes strongly associated with obesity, diabetes, and dyslipidemia. MASLD and MASH have complex pathogenesis modulated not only by the liver but also by muscle, adipose tissue, pancreas, gut microbiome, and immune and central nervous systems. This complex pathology, coupled with insulin resistance, lipid and bile acid changes, and congenital genetic predisposition, induces liver injury due to oxidative stress, endoplasmic reticulum stress, and autophagy dysfunction. Additionally, MASLD and MASH contribute to diseases such as cirrhosis, atherosclerosis, chronic kidney disease, lung disease, and cancer in various organs, leading to systemic multi-organ damage. Even though enthusiastic development of new drugs for MASLD and MASH has been underway, we are still lacking progress in generating therapeutic agents based on multiorgan-related pathomechanisms. In this special issue, we welcome clinical and basic studies on extrahepatic lesions, as well as new findings related to liver pathology in MASLD and MASH. Topic Editors welcome manuscripts that particularly focus on new therapies and new signaling pathways related to the multiorgan-linkage of MASLD and MASH.
Keywords: Multi-organ linkage, MASLD, MASH, MAFLD, diabetes, dyslipidemia, adipose tissue, muscle, pancreas, kidney, lung, gut microbiome, immunology, GPCR, cancer, atherosclerosis, oxidative stress, insulin resistance, biomarker, drug target, NAFLD, NASH
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
